Stem Cell Core
The Stem Cell Core Facility aims to accelerate stem cell research at City of Hope by providing critical stem cell resources and technical support. We will provide customized services for human iPSC derivation, characterization, and gene editing. These human iPSCs will become valuable tools for disease modeling, drug discovery and therapeutic development.
- Conferring stemness to engineered T cells through induced pluripotent stem cells for adoptive immunotherapy
- Assessing the impact of EPZ-6438 on stem cell aging and aging-related diseases
- Induced pluripotent stem cells for mitochondrial disease
Human iPSC derivation and characterization
We will provide customized services for deriving human disease-specific iPSCs to cater to individual research needs. We will also characterize these cells to confirm their pluripotency.
Human iPSC gene editing
We will use genome-editing technology, such as CRISPR-Cas9 editing to genetic-engineer human iPSCs to introduce or correct gene mutations.
Research and development
The Stem Cell Core may help develop protocols for certain lineage-specific differentiation for human iPSCs.
Yanhong Shi, Ph.D., is a professor in the Department of Stem Cell Biology and Regenerative Medicine at the Beckman Research Institute of City of Hope, performing research on stem cell biology and regenerative medicine. Dr. Shi is a beneficiary of the Christopher Family Endowed Innovation Fund for Alzheimer’s Disease and Breast Cancer Research in Honor of Vineta Christopher.
Contact the Team
TC hoods and incubators, laminar-flow hood, dissection microscope, liquid nitrogen tank, fridge and freezer, and water bath
In a given year, City of Hope conducts more than 400 clinical trials enrolling more than 6,000 patients.
City of Hope is focused on basic and clinical research in cancer, diabetes and other life-threatening diseases.